ADPT

ANALYST NOTE: ADAPTIVE BIOTECHNOLOGIES (ADPT) Date: June 13, 2026

(1) Structural Readiness The stock is currently trading at $20.96, which aligns exactly with the established conservative entry level of $20.96. The price action represents a confirmed breakout from a constructive base, with the current price extending +0.0% from the entry point. The setup is not merely forming; the breakout signal has fired, indicating that the structural consolidation phase has concluded and the market is now pricing in the new information. The volatility profile, measured by the Average True Range (ATR), is currently at 5.7%, which sits within the high historical sweet spot (4–6%) for structural quality. This level of volatility suggests a robust, active market environment capable of supporting a sustained move, rather than a fragile or weakly trending name. The structure is tight, and the breakout is confirmed.

(2) The Thesis Layer The primary secular thesis driving this setup is the "Biotech & GLP-1 → Diagnostics" theme, where Adaptive Biotechnologies acts as a direct beneficiary. The company is positioned at the intersection of precision diagnostics and the expanding landscape of immuno-oncology. While the company has historically been viewed through a broad biotech lens, the specific exposure here is to the Minimal Residual Disease (MRD) market, which is a critical enabler for the efficacy of modern cancer therapies, including those in the GLP-1 adjacent space of metabolic and immune health. The company is not a peripheral player; it is a tier-1 direct beneficiary, providing the essential data infrastructure (clonoSEQ) required for the clinical trials and regulatory approvals that drive the broader biotech sector. The thesis is reinforced by the company's recent strategic pivot to separate its MRD diagnostics from its Immune Medicine platform, effectively isolating and highlighting the high-growth diagnostic engine.

(3) The Business Adaptive Biotechnologies operates as a commercial-stage entity focused on decoding the adaptive immune system to diagnose and treat disease. Its core business model relies on proprietary sequencing technologies, specifically the immunoSEQ platform, which generates data for both clinical diagnostics and drug discovery.

As of the most recent earnings data (May 5, 2026), the MRD business has become the dominant revenue driver. Management raised full-year MRD revenue guidance to a range of $260 million to $270 million, citing "strength" in the business. In the first quarter of 2026 alone, MRD revenue grew 53% year-over-year to $67.1 million, with clinical and pharmaceutical contributions split at 65% and 35%, respectively. The volume of clonoSEQ tests reached a quarterly record of nearly 32,600, up 9% sequentially.

The company's backlog is robust, standing at approximately $254 million, a 24% increase year-over-year, driven largely by new bookings from regulated studies. These bookings include several registrational trials where MRD is used as a primary or co-primary endpoint in multiple myeloma and CLL. Furthermore, the company has expanded payor coverage to over 300 million lives for ALL and MM, and over 270 million lives for CLL.

Financially, the company is showing significant operational leverage. Sequencing gross margins (excluding MRD milestones) improved to 70% in Q1 2026, up from 62% a year ago. Cash flow from operations improved dramatically, with net cash used in operations dropping 52% to $46.0 million in 2025 compared to $95.2 million in 2024. The company holds $227.2 million in cash and marketable securities as of December 31, 2025.

(4) The Archetype and Conviction Adaptive Biotechnologies fits the Quality Compounder archetype. This classification is supported by the company's transition from a high-burn growth story to a profitable, cash-flow-positive entity with a clear path to sustained growth. The "Quality" aspect is evidenced by the expanding gross margins (70%), the strong backlog ($254M), and the reduction in cash burn. The "Compounder" aspect is driven by the secular tailwinds in MRD testing, which management expects to grow volumes by at least 35% in 2026.

Valuation context from the financial spine indicates a forward consensus EPS of -0.46 for FY1 and -0.25 for FY2, suggesting the market is still pricing in a path to profitability, though the operational improvements (reduced cash burn, margin expansion) suggest this timeline may be accelerating. The ATR of 5.7% confirms the stock is in a high-quality volatility range, suitable for a structural breakout. The conviction is high due to the convergence of strong earnings momentum, a clear strategic separation of the MRD business (which unlocks value), and a massive, under-penetrated total addressable market (TAM) of approximately $6.2 billion for MRD.

(5) Invalidation, Strengthening, and Gaps Strengthening Factors:

• Continued execution on the 35% volume growth target for 2026.
• Successful completion of the proposed separation of the MRD and Immune Medicine businesses, which management believes will unlock greater value.
• Further expansion of payor coverage or inclusion of MRD as a primary endpoint in additional major registrational trials.

Invalidation Factors:

• A significant miss on the raised full-year MRD revenue guidance ($260M–$270M).
• A reversal in the trend of cash burn, where net cash used in operations increases significantly despite revenue growth.
• Failure to secure new bookings or a decline in the backlog, indicating a slowdown in clinical trial demand.

Gaps in Evidence:

• While the separation plan was announced in mid-June 2026, the specific financial structure of the split (e.g., spin-off vs. sale) and the immediate impact on the standalone balance sheet of the new entities are not yet fully detailed in the provided evidence.
• The long-term profitability timeline for the Immune Medicine platform remains a variable, as the company is currently focusing on the MRD business.
• There is no specific evidence regarding the pricing power or reimbursement rate changes for clonoSEQ tests in the current quarter beyond the general coverage expansion.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: MRD revenue grew 53% YoY to $67.1M in Q1 2026 with raised full-year guidance of $260M-$270M; Backlog up 24% YoY to $254M driven by registrational trials; Gross margins expanded to 70% and cash burn reduced 52% in 2025. Key risks: Execution risk on the planned business separation; potential slowdown in clinical trial enrollment affecting test volumes; regulatory or reimbursement changes impacting payor coverage. Sizing hint: Position size should reflect the high structural quality (ATR 5.7%) and confirmed breakout, allowing for standard aggressive sizing within risk parameters. Expected path: Management expects MRD volumes to grow at least 35% in 2026; the separation of the MRD and Immune Medicine businesses is expected to unlock value by allowing the market to value the profitable diagnostic unit separately from the R&D-heavy platform. Expected horizon: 12 to 18 months for the separation to fully price in and for the 2026 volume growth targets to be realized. Failure mode to watch: A miss on the raised full-year MRD revenue guidance or a significant increase in cash burn that contradicts the 2025 trend.